Only 14 pages are availabe for public view
RA is a chronic, systemic, and destructive inflammatory disease that involves both small and large joints due to variable combination of genetic, environmental, and immunological factors.
EORA refers to the de novo development of RA in persons older than or equal to 60 years and it is considered to have different features in relation to YORA.
There was some controversy about whether and how those patients with EORA might differ from those with YORA. That`s why this study was done to identify the clinical features of EORA and their impact on disease outcome.
It included 2 groups of patients with Rheumatoid Arthritis;
(1) EORA, including thirty patients whose RA started at or above the age of 60 years (2) YORA, including thirty patients whose RA started below the age of 60 years as a control group.
Results of this study showed that EORA patients have more frequent constitutional symptoms and more incidence of large joints involvement. In addition, EORA patients have higher inflammatory markers, higher disease activity and less seropositivity than YORA patients.
EORA patients also suffered more frequently from RA-related co-morbidities. And these co morbidities have major considerations when choosing the most suitable therapy for EORA patients. Prudent use and careful follow-up of all treatments are also required because of the increased risk of adverse events in elderly patients.
No difference was observed between EORA and YORA patients, who have the same disease duration, regarding disease severity, radiological changes and associated joint deformity.